Most cited papers in Immunotherapy and Immune Responses
What are the most cited papers in Immunotherapy and Immune Responses?
The most cited paper in Immunotherapy and Immune Responses is "PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer" (Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al., 2016), with 30,915 citations. Next come "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" (15,337) and "Dendritic cells and the control of immunity" (14,440).
Showing 50 of 100 papers. Every paper with more than 2,901 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · Breast Care | 2016 | 30,915 |
| 2 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Frank Stephen Hodi et al. · New England Journal of Medicine | 5 Jun 2010 | 15,337 |
| 3 | Dendritic cells and the control of immunity Jacques Banchereau, Ralph M. Steinman · Nature | Mar 1998 | 14,440 |
| 4 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne Louise Topalian et al. · New England Journal of Medicine | 14 Jun 2012 | 12,842 |
| 5 | Prospective identification of tumorigenic breast cancer cells Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences | 10 Mar 2003 | 10,455 |
| 6 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei et al. · New England Journal of Medicine | 27 Sep 2015 | 9,557 |
| 7 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin et al. · New England Journal of Medicine | 31 May 2015 | 8,266 |
| 8 | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie Renee Brahmer et al. · New England Journal of Medicine | 14 Jun 2012 | 8,100 |
| 9 | Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Jason D. Fontenot, Marc A. Gavin, Alexander Yu Rudensky · Nature Immunology | 3 Mar 2003 | 7,778 |
| 10 | Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position Jason Daniel Buenrostro, Paul G. Giresi, Lisa C. Zaba et al. · Nature Methods | 6 Oct 2013 | 7,255 |
| 11 | Oncology Meets Immunology: The Cancer-Immunity Cycle Daniel S. Chen, Ira Mellman · Immunity | Jul 2013 | 7,122 |
| 12 | PD-1 blockade induces responses by inhibiting adaptive immune resistance Paul C. Tumeh et al. · Nature | 25 Nov 2014 | 6,760 |
| 13 | Immunobiology of Dendritic Cells Jacques Banchereau, Francine Brière, Christophe Caux et al. · Annual Review of Immunology | Apr 2000 | 6,652 |
| 14 | TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells Taiwen Li, Jing‐Yu Fan, Binbin Wang et al. · Cancer Research | 31 Oct 2017 | 6,637 |
| 15 | Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science | 28 Sep 2006 | 6,620 |
| 16 | The chemokine system in diverse forms of macrophage activation and polarization Alberto Mantovani, Antonello Sica, Silvano Sozzani et al. · Trends in Immunology | 6 Nov 2004 | 6,595 |
| 17 | A Toll-like receptor recognizes bacterial DNA Hiroaki Hemmi, Osamu Takeuchi, Taro Kawai et al. · Nature | 7 Dec 2000 | 6,498 |
| 18 | Understanding the tumor immune microenvironment (TIME) for effective therapy Mikhail Binnewies, Edward W. Roberts, Kelly Kersten et al. · Nature Medicine | 20 Apr 2018 | 6,338 |
| 19 | Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Federica Sallusto, Danielle Lenig, Reinhold Förster et al. · Nature | Oct 1999 | 5,898 |
| 20 | Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells Jung‐Hyun Park, Stanley Adoro, Terry I. Guinter et al. · Nature Immunology | 31 Jan 2010 | 5,851 |
| 21 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer Ann Wargo et al. · Cell | Feb 2017 | 5,686 |
| 22 | Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Alberto Mantovani, Silvano Sozzani, Massimo Locati et al. · Trends in Immunology | 21 Oct 2002 | 5,595 |
| 23 | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine | 28 Jul 2010 | 5,577 |
| 24 | Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases Shimon Sakaguchi, N Sakaguchi, M Asano et al. · The Journal of Immunology | Aug 1995 | 5,571 |
| 25 | Elements of cancer immunity and the cancer–immune set point Daniel S. Chen, Ira Mellman · Nature | 2017 | 5,520 |
| 26 | PD-1 and Its Ligands in Tolerance and Immunity Mary E Keir, Manish J. Butte, Gordon James Freeman et al. · Annual Review of Immunology | 3 Jan 2008 | 5,426 |
| 27 | Cancer immunoediting: from immunosurveillance to tumor escape Gavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda et al. · Nature Immunology | 29 Oct 2002 | 5,415 |
| 28 | Regulatory T Cells and Immune Tolerance Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura et al. · Cell | May 2008 | 5,393 |
| 29 | Involvement of chemokine receptors in breast cancer metastasis Anja Müller, Bernhard Homey, Hortensia Soto et al. · Nature | Mar 2001 | 5,368 |
| 30 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst et al. · Nature | 25 Nov 2014 | 5,353 |
| 31 | Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Federica Sallusto, Antonio Lanzavecchia · The Journal of Experimental Medicine | Apr 1994 | 5,185 |
| 32 | Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Tyler Jay Curiel et al. · Nature Medicine | 22 Aug 2004 | 5,148 |
| 33 | Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion Haidong Dong, Scott Eric Strome, Diva R. Salomão et al. · Nature Medicine | 24 Jun 2002 | 5,107 |
| 34 | The immune contexture in human tumours: impact on clinical outcome Wolf H. Fridman, Franck Pagès, Catherine Sautès‐Fridman et al. · Nature reviews. Cancer | 15 Mar 2012 | 5,087 |
| 35 | The future of immune checkpoint therapy Padmanee Sharma, James Patrick Allison · Science | 2 Apr 2015 | 4,925 |
| 36 | Neoantigens in cancer immunotherapy Ton N. Schumacher, Robert D. Schreiber · Science | 2 Apr 2015 | 4,884 |
| 37 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer et al. · The Lancet | 12 Dec 2016 | 4,817 |
| 38 | Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini et al. · Immunity | Oct 2013 | 4,813 |
| 39 | The Dendritic Cell System and its Role in Immunogenicity Ralph M. Steinman · Annual Review of Immunology | Apr 1991 | 4,722 |
| 40 | mRNA vaccines — a new era in vaccinology Norbert Pardi, Michael J. Hogan, Frederick Porter et al. · Nature Reviews Drug Discovery | 12 Jan 2018 | 4,701 |
| 41 | Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 WanJun Chen, Wenwen Jin, Neil J. Hardegen et al. · The Journal of Experimental Medicine | 15 Dec 2003 | 4,695 |
| 42 | A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry Ildo Nicoletti, Graziella Migliorati, Maria Cristina Pagliacci et al. · Journal of Immunological Methods | Jun 1991 | 4,648 |
| 43 | Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Alexandra Snyder et al. · New England Journal of Medicine | 20 Nov 2014 | 4,426 |
| 44 | Innate and adaptive immune cells in the tumor microenvironment Thomas F. Gajewski, Hans Wilhelm Schreiber, Yang‐Xin Fu · Nature Immunology | 18 Sep 2013 | 4,299 |
| 45 | A guide to cancer immunotherapy: from T cell basic science to clinical practice Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo · Nature reviews. Immunology | 20 May 2020 | 4,257 |
| 46 | Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok et al. · New England Journal of Medicine | 2 Jun 2013 | 4,257 |
| 47 | Toll-like receptor control of the adaptive immune responses Akiko Iwasaki, Ruslan M. Medzhitov · Nature Immunology | 28 Sep 2004 | 4,186 |
| 48 | Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity Michael S. Rooney, Sachet Ashok Shukla, Catherine J. Wu et al. · Cell | 2015 | 4,173 |
| 49 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster et al. · New England Journal of Medicine | Dec 2018 | 4,157 |
| 50 | Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments Oliver M. Grauer, Pieter Wesseling, Gosse J. Adema · Brain Pathology | 4 Sep 2009 | 4,018 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.